The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

Zhulina, Yaroslava; Cao, Yang; Amcoff, Karin; Carlson, Marie; Tysk, Curt; Halfvarson, Jonas

doi:10.1111/apt.13731

Cited by 66 publications

(56 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association in this study may be related to the higher rate of anti‐TNF α agent use, hence a greater potency of suppressing inflammation, in patients with Crohn's disease compared to ulcerative colitis (Crohn's disease 40% vs. ulcerative colitis 7%, P < 0.001). We however did not find an association between use of anti‐TNF α agents and the risk of symptomatic relapse, nor did the lone previous study which also reported the effect of anti‐TNF α on symptomatic relapse in adults with IBD in clinical remission . Nevertheless, the number of anti‐TNF α users that subsequently relapsed, in our cohort and the latter study, were low, which may have impeded determination of an accurate association.…”

Section: Discussioncontrasting

confidence: 92%

See 1 more Smart Citation

Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission

Diederen

Hoekman

Leek

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 92%

“…Faecal calprotectin level has already been shown to be predictive of symptomatic relapse in adult patients with IBD . Similar to our results, the majority of studies in adults found a higher FC level in patients who developed a relapse compared with those who remained in clinical remission .…”

Section: Discussionsupporting

confidence: 91%

Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission

Diederen

Hoekman

Leek

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…FC has been shown to be a reliable marker for assessing IBD disease activity [24] and in predicting mucosal healing and risk of relapse in CD patients [25][26][27]. CRP was also found to be a predictor of surgery in subgroups of patients with either UC or CD [28].…”

Section: Treatment Goals and Therapeutic Approaches -Differences Withmentioning

confidence: 99%

The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives

2017

View full text Add to dashboard Cite

Data on the elderly population with inflammatory bowel disease (IBD) are scarce, as this population is normally excluded from clinical trials. With an ageing population and an overall increasing prevalence of IBD; the incidence of IBD in elderly is rising. Comorbidities, wide differential diagnosis and polypharmacy make the diagnosis and management of the disease in elderly more challenging compared to that in younger adults. The knowledge of specific requirements for the management and treatment of IBD in advanced age may help in the framing of the definition of the appropriate care of this patient group. This manuscript reviews the most recent knowledge in the epidemiology, diagnosis and management of IBD in this population.

show abstract

“…With regard to the role of fCP in predicting response to thiopurine therapy, there are to our knowledge to date no published studies that interpret its predictive utility. The detailed role of fCP in IBD along with its ability to predict response to other forms of treatment than thiopurines alone are described in a number of up to date reviews (11,12,63,(80)(81)(82)(83)(84).…”

Section: Fecal Biomarkersmentioning

confidence: 99%

Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease

2020

View full text Add to dashboard Cite

The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's response to therapeutics could decrease the time from active disease to clinical remission and mucosal healing. The prospect of such individualized treatment of IBD would be aided by accurate biomarkers, both fecal and serological, which have to date shown value as indicators of IBD activity. Here we review the utility of generic biomarkers for inflammation or mucosal healing, such as calprotectin, C-reactive protein (CRP), and fecal hemoglobin (fHb) as predictors of response to treatment of IBD. We further provide a deeper insight into the utility of monitoring the thiopurine treatment by thiopurine metabolites or alternative hematologic parameters. In light of multiple recent publications of biomarkers and biological therapy, our focus in this review is predicting response to thiopurine treatment only, that is, Azathioprine and 6-Mercaptopurine.

show abstract

The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

Cited by 66 publications

References 35 publications

Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission

Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission

The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives

Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease

Contact Info

Product

Resources

About